0000950170-24-139616.txt : 20241223 0000950170-24-139616.hdr.sgml : 20241223 20241223163332 ACCESSION NUMBER: 0000950170-24-139616 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241223 FILED AS OF DATE: 20241223 DATE AS OF CHANGE: 20241223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sullivan Lara CENTRAL INDEX KEY: 0001769457 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40881 FILM NUMBER: 241574137 MAIL ADDRESS: STREET 1: C/O REXAHN PHARMACEUTICALS, INC. STREET 2: 15245 SHADY GROVE ROAD, SUITE 455 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pyxis Oncology, Inc. CENTRAL INDEX KEY: 0001782223 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831160910 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: (617) 221-9059 MAIL ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 4 1 ownership.xml 4 X0508 4 2024-12-23 false 0001782223 Pyxis Oncology, Inc. PYXS 0001769457 Sullivan Lara C/O PYXIS ONCOLOGY, INC. 321 HARRISON AVENUE, 11TH FL. SUITE 1 BOSTON MA 02118 true true false false Chief Executive Officer false Stock Option (Right to Buy) 1.67 2024-12-23 4 A false 1135000 0 A 2034-12-23 Common Stock 1135000 1135000 D The shares subject to this option vest in full on December 23, 2025, subject to the Reporting Person's continued employment through the vesting date. /s/ Pamela Connealy, Attorney-in-Fact for Lara Sullivan 2024-12-23